|
|
Venous thromboembolism: The past and the present
|
|
|
|
Outline
|
|
|
|
The Past I
|
|
|
|
The Past II
|
|
|
|
The Past III
|
|
|
|
Classes of new anticoagulants
|
|
|
|
Treatment Data Available
|
|
|
|
Biotinylated idraparinux : Structure and product profile
|
|
|
|
Equinox
|
|
|
|
EQUINOX VTE recurrences at 6 months
|
|
|
|
EQUINOX Safety data at 6 months
|
|
|
|
Study Design
|
|
|
|
Primary efficacy outcome analysis
|
|
|
|
Efficacy results
|
|
|
|
Primary safety outcome analysis
|
|
|
|
Bleeding results
|
|
|
|
Idrabiotaprinux is a good and attractive alternative for VKA in the treatment of DVT and PE
|
|
|
|
Dabigatran Etexilate
|
|
|
|
Recover I
|
|
|
|
Recover I VTE recurrences at 6 months
|
|
|
|
Recover I Safety data at 6 months
|
|
|
|
Resonate
|
|
|
|
Resonate
|
|
|
|
Still to come
|
|
|
|
Human Factor Xa/rivaroxaban complex
|
|
|
|
EINSTEIN: study designs
|
|
|
|
EINSTEIN DVT: primary efficacy outcome
|
|
|
|
EINSTEIN DVT: principal safety outcome analysis
|
|
|
|
Still to come
|
|
|
|
Others joining soon
|
|
|
|
Conclusions
|
|
|
|
Future
|
|
|
|
Influence of statin therapy on recurrent pulmonary embolism
|
|
|
|
Future
|
|
Deel deze pagina met collega's en vrienden: